Eisai Co., Ltd. (4523)

6,886.0
+34.0(+0.50%)
  • Volume:
    1,131,600
  • Bid/Ask:
    6,886.0/6,913.0
  • Day's Range:
    6,792.0 - 6,925.0
  • Type:Equity
  • Market:Japan
  • ISIN:JP3160400002

4523 Overview

Prev. Close
6,852
Day's Range
6,792-6,925
Revenue
691.25B
Open
6,899
52 wk Range
6,705-12,765
EPS
218.03
Volume
1,131,600
Market Cap
1.97T
Dividend (Yield)
160.00
(2.34%)
Average Vol. (3m)
1,179,185
P/E Ratio
31.43
Beta
1.1
1-Year Change
-10.84%
Shares Outstanding
286,689,848
Next Earnings Date
Feb 04, 2022
What is your sentiment on Eisai Co., Ltd.?
or
Market is currently closed. Voting is open during market hours.

Eisai Co., Ltd. Company Profile

Employees
11237
Market
Japan

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer’s disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson’s disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellSellSellStrong Sell
Technical IndicatorsStrong SellBuyStrong BuyStrong SellStrong Sell
SummarySellNeutralNeutralStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.